



Provider Issue Briefing

CONTRA COSTA
HEALTH PLAN
595 Center Avenue
Suite 100
Martinez, CA 94553
925.313.6000
Date: June 2023

Contra Costa Health Plan Pharmacy and Therapeutics Committee (P&T)


The CCHP P&T committee met on 6/1/2023. Updates from the meeting are outlined below:

****Changes to the PDL will be effective by mid-August 2023****

Updates/Announcements:

1. Schedule for Medi-Cal Rx Reinstatement of Prior Authorization Requirements:

Reinstatement Phase II – Phase IV



Medi-Cal Rx is moving forward with reinstatement for beneficiaries 22 years of age and older with the initiation of Phase IV through a series of lifts impacting claim utilization management (UM) edits (such as age limits, labeler restrictions, quantity limits, diagnosis, etc.).

The purpose of this alert is to notify pharmacy providers and prescribers that on August 4, 2023, Phase IV, Lift 1 (P4/L1) will be the first lift impacting claim UM edits for beneficiaries 22 years of age and older.

Note: Claims for beneficiaries 21 years of age and younger will not be impacted.

On September 22, 2023, PA requirements will be reinstated for new start enteral nutrition products for members **22 years of age and older**. "New starts" are defined as new enteral nutrition therapy not previously prescribed to the member during the 15-month lookback period. PA requests may also be submitted in advance of the retirement of the Transition Policy (anticipated implementation in November 2023) for enteral nutrition products, for members 22 years of age and older, beginning September 22, 2023.

For additional details including the specific medications in each phase, please go to the DHCS Medi-Cal Rx website at <https://www.medi-calrx.dhcs.ca.gov/home/education/> or contact CCHP Pharmacy Department for more details.

2. Medi-Cal Rx Formulary Changes:

Medi-Cal Rx has been updating their Contract Drug List (CDL) on a monthly basis. These updates can be found on the DHCS Medi-Cal Rx website at <https://medi-calrx.dhcs.ca.gov/provider/pharmacy-news> or contact the CCHP Pharmacy Department for additional details.

Quick reference table for all changes to the Preferred Drug List (PDL) and/or Prior Authorization (PA) criteria (for full details of each change, please see individual drugs listed below this table or contact the CCHP Pharmacy Department):	
Changes Made	Drug Name
Created new PA criteria:	Monoferic (ferric derisomaltose) Gonadotropin Releasing Hormone Antagonists
Modified PA criteria:	Anti-obesity medications Freestyle Libre Reader and Sensor Insulin glargine (Lantus)(Semglee)(Basaglar) Naltrexone IM injection (Vivitrol)
ADDED to the CCHP formulary:	Atomoxetine 80 mg and 100 mg capsules
Removed from CCHP formulary:	Colchicine 0.6 mg capsules

- **New Pharmacy Criteria for Monoferic (ferric derisomaltose):** added to the criteria as a preferred IV iron-Member must be meet laboratory evidence of iron deficiency anemia and trial and failure, intolerance or relative contraindication to oral iron supplementation
- **New Pharmacy Criteria for Gonadotropin Releasing Hormone Antagonists:** For a diagnosis of endometriosis associated with moderate to severe pain, documentation of trial and failure of an analgesic pain reliever (ie. NSAIDS) taken in combination with combined estrogen progestin oral contraceptive pills. For a diagnosis of heavy menstrual bleeding associated with uterine leiomyomas, a documented trial and failure of estrogen-progestin contraceptive therapy
- **Modification of pharmacy criteria for anti-obesity medications:** Added that documentation of trial of lifestyle modifications requirement can be met by documentation that the member has been and is currently following a dietary and behavior modification program for weight loss for several months such as Weight Watchers, 18 Reasons, etc..
- **Modification of pharmacy criteria for Freestyle Libre Reader and Sensor:** removal of the requirement that previously stated that documentation why the member cannot use finger stick testing was required.
- **Modification of pharmacy criteria for insulin glargine (Lantus) (Semglee)(Basaglar):** changed requirement of previous trial and failure of a preferred biosimilar from requiring trial and failure of one formulary biosimilar to requiring trial and failure of two formulary biosimilars.
- **Modification of pharmacy criteria for naltrexone IM injection (Vivitrol):** modified criteria to remove the requirement that the member be a part of a comprehensive treatment program for alcohol dependence.

There are numerous ways to view the CCHP Preferred Drug List:

CCHP updates the Preferred Drug List (PDL) after each quarterly Pharmacy & Therapeutics Committee meeting. CCHP invites and encourages practitioners to access each update through the following means:

- An interactive searchable formulary is available within Epic (contact the Epic team with any questions related to functionality).
- A printable copy of the CCHP PDL can be found here: <http://cchealth.org/healthplan/pdf/pdl.pdf>
- A searchable copy of the CCHP PDL can be found here: <https://cchealth.org/healthplan/formulary.php>
- **EPOCRATES – free mobile & online formulary resource**
 - CCHP providers may add the CCHP formulary to their mobile devices using the following steps:
 - Open the Epocrates application on your mobile device.
 - Click on the “formulary” button on the home screen.
 - Click “add new formulary” button on the bottom of the screen.
 - Use the search box to locate “Contra Costa Health Plan” Medi-Cal or Commercial formulary. Click on each formulary that you would like to add, and then click the “add formulary” button.



Epocrates mobile is supported on the iOS (iPhone, iTouch, iPad), Android, & BlackBerry platforms

If you have any questions about the installation or use of Epocrates, please contact Epocrates Customer Support at goldsupport@epocrates.com or at (800)230-2150.

Providers may request a copy of CCHP pharmacy management procedures or specific drug PA criteria by contacting the pharmacy unit directly at 925-957-7260 x1, or via the email listed below:

P&T updates and DUR educational bulletins can be viewed online at
<http://cchealth.org/healthplan/provider-pharmacy-therapeutics.php>

Questions and comments may be directed to CCHP Pharmacy by emailing
joseph.cardinalli@cchealth.org
